- Further proof of great versatility of Altamira’s platform for extrahepatic RNA delivery
- Circular mRNA significantly increasing protein expression vs. linear mRNA
- Filed provisional patent application, further expanding IP portfolio
HAMILTON, Bermuda I December 31, 2024 I Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (OTCQB:CYTOF), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that its nanoparticle-based delivery platform was successfully tested also for circular mRNA. In vitro experiments demonstrated successful transfection of cells and significantly higher protein expression than with linear mRNA, based on which the Company has filed a provisional patent application with the United States Patent Office (USPTO). Altamira will start offering its platform to biotech and pharma companies for use with circular RNA under the CycloPhore™ label, complementing its offerings for siRNA (OligoPhore™) and mRNA (SemaPhore™).
“We are very excited about the potential for CycloPhore as circular mRNA has been attracting great interest in drug development thanks to enhanced protein expression and greater stability compared to linear mRNA,” commented Covadonga Pañeda, Ph.D., Altamira Therapeutics’ Chief Operating Officer. “For instance, circular mRNA could allow for lower dosing and less frequent administrations than linear mRNA which may be very important for certain therapeutic indications or vaccines. CycloPhore provides further testimony to the versatility of our delivery platform across different RNA modalities. We expect that the expansion of our platform into this exiting new RNA modality together with the platform’s ability to deliver extrahepatically and promote strong endosomal escape will make CycloPhore an attractive tool for drug developers looking for delivery vehicles that fit their specific needs.”
About Altamira Therapeutics
Altamira Therapeutics (OTCQB:CYTOF) is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (OligoPhore™ / SemaPhore™ / CycloPhore™ platforms). The Company currently has two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. The versatile delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing. In addition, Altamira holds a 49% stake (with additional economic rights) in Altamira Medica AG, which holds its commercial-stage legacy asset Bentrio®, an OTC nasal spray for allergic rhinitis. Further, the Company is in the process of partnering / divesting its inner ear legacy assets. Founded in 2003, Altamira is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit: https://altamiratherapeutics.com/
SOURCE: Altamira Therapeutics
Post Views: 361
- Further proof of great versatility of Altamira’s platform for extrahepatic RNA delivery
- Circular mRNA significantly increasing protein expression vs. linear mRNA
- Filed provisional patent application, further expanding IP portfolio
HAMILTON, Bermuda I December 31, 2024 I Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (OTCQB:CYTOF), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that its nanoparticle-based delivery platform was successfully tested also for circular mRNA. In vitro experiments demonstrated successful transfection of cells and significantly higher protein expression than with linear mRNA, based on which the Company has filed a provisional patent application with the United States Patent Office (USPTO). Altamira will start offering its platform to biotech and pharma companies for use with circular RNA under the CycloPhore™ label, complementing its offerings for siRNA (OligoPhore™) and mRNA (SemaPhore™).
“We are very excited about the potential for CycloPhore as circular mRNA has been attracting great interest in drug development thanks to enhanced protein expression and greater stability compared to linear mRNA,” commented Covadonga Pañeda, Ph.D., Altamira Therapeutics’ Chief Operating Officer. “For instance, circular mRNA could allow for lower dosing and less frequent administrations than linear mRNA which may be very important for certain therapeutic indications or vaccines. CycloPhore provides further testimony to the versatility of our delivery platform across different RNA modalities. We expect that the expansion of our platform into this exiting new RNA modality together with the platform’s ability to deliver extrahepatically and promote strong endosomal escape will make CycloPhore an attractive tool for drug developers looking for delivery vehicles that fit their specific needs.”
About Altamira Therapeutics
Altamira Therapeutics (OTCQB:CYTOF) is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (OligoPhore™ / SemaPhore™ / CycloPhore™ platforms). The Company currently has two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. The versatile delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing. In addition, Altamira holds a 49% stake (with additional economic rights) in Altamira Medica AG, which holds its commercial-stage legacy asset Bentrio®, an OTC nasal spray for allergic rhinitis. Further, the Company is in the process of partnering / divesting its inner ear legacy assets. Founded in 2003, Altamira is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit: https://altamiratherapeutics.com/
SOURCE: Altamira Therapeutics
Post Views: 361
